Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC

Precigen Doses First Patient in Phase 1 Trial of PRGN-3005 for Advanced OC
Precigen has begun dosing participants in a Phase 1 trial testing its experimental therapy PRGN-3005 UltraCAR-T in patients with advanced, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. The open-label trial (NCT03907527), which is still recruiting patients, will be carried out in collaboration with the University of Washington and the Fred Hutchinson Cancer Research Center. Its aims to evaluate the safety and optimal dose of PRGN-3005 given intravenously (into the bloodstream) or intraperitoneally (into the abdomen). Eligible participants are women with advanced ovarian, fallopian tube, or primary peritoneal cancer who are resistant to platinum-based therapies and whose cancer progressed after receiving standard-of-care treatment or are not eligible for currently available therapies. "This is an important milestone in our efforts to develop a new treatment option for patients with ovarian cancer," Helen Sabzevari, PhD, president of Precigen, said in a
Subscribe or to access all post and page content.